In 2022, Dr. Chuck Silberstein earned $813.47K in total compensation at Applied Therapeutics, including $588.47K salary and $225.00K bonus. Most recently acquired 47,900 shares in Jan 2022. Currently holds stock worth $39.77K. Led Applied Therapeutics as CEO for 1 years.
Compensation History
Annual executive compensation data for Dr. Chuck Silberstein, including salary, bonuses, and stock awards.
Year
2022
Total Compensation
$813.47K
Salary
$588.47K
Bonus
$225.00K
Other
$0.00
Salary
$588.47KBoard Justification
The compensation philosophy is designed to align the interests of executives with those of stockholders, focusing on performance and retention strategies.
Bonus
$225.00KBoard Justification
Dr. Shendelman received a bonus for 2022 performance, payable in equal parts cash and RSUs vested in full as of the date of grant. A total of $225,000 of this bonus is payable in cash, 50% (representing $112,500) of which was paid in January 2023, and the remaining 50% (representing $112,500) of which will be paid on or about June 30, 2023.
Other Compensation
$0.00Board Justification
No other compensation is reported for 2022.
Restricted Stock
Board Justification
No vested stock is reported for 2022 as the RSUs granted in early 2023 will be included in the 2023 compensation report.
Performance Metrics
The performance metrics for the CEO's compensation include individual performance, company performance, and other relevant factors as determined by the compensation committee.
Dr. Chuck Silberstein
Ex-CEO of Applied Therapeutics
Education
Master of Business Administration in finance from Columbia University and a Doctor of Medicine from the Albert Einstein College of Medicine
Field of Expertise
Finance & Banking - Finance
Sector of Economy
Healthcare
Born
January 1, 1970 - 55 years ago
CEO of Applied Therapeutics for
1 year 8 months (May 2020 - Jan 2022)
Previous Experience
Senior Vice President of Corporate Business Development at Allergan plc, Executive Director, Senior healthcare analyst for J.P. Morgan Asset Management, Senior Healthcare Analyst at The Boston Company Asset Management, Healthcare Analyst at Goldman Sachs Asset Management
Other Applied Therapeutics CEOs
Holdings
Track Dr. Chuck Silberstein's stock holdings and portfolio value over time.
Total Stock Sold
$111.54K
$111.54K
5,047 APLT shares
What if they kept their stock?
If Dr. Chuck Silberstein didn't sell their stock, today they would have:
Extra APLT5,047 shares worth $1.09K.
This is -99.02% and $110.45K less than what they got when they sold the stock.
Insider Trading
Dr. Chuck Silberstein's recent stock transactions, purchases, and sales filed with the SEC.
47,900 shares
APLT
Jan 7, 2022
Received
47,900 shares
APLT
Dec 14, 2021
Received
47,900 shares
APLT
Dec 14, 2021
Received
$108.11K
APLT at $21.42/share
Jun 8, 2021
Sale
61,000 shares
APLT
Jun 4, 2020
Received
Rivals
Compare Dr. Chuck Silberstein with competitor CEOs and industry peers.